Handelsavisen
prelaunch
Companies Healthcare OSUR.O
OS
OSUR.O NASDAQ Diversified Medical Equipment & Supplies

OraSure Technologies Inc

$4,25
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-62,6 %
ROE
-20,2 %
Net margin
-59,8 %
Debt / equity
0,00
Beta
52w range
Volume
11,4k
Day range
$3,91–$4,33
Prev close
$3,98
Open
$3,97
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

OraSure Technologies Inc develops and markets rapid diagnostic tests and related products for the detection of infectious diseases, primarily HIV, and provides point-of-care diagnostic solutions for healthcare professionals and consumers.

Business. OraSure Technologies Inc (OSUR.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, focusing on medical devices and related supplies. It is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY2 analysts
1 buy1 hold0 sell
Avg 12m price target4,00

Analyst recommendations

2 analysts · consensus Buy
Buy1
Hold1
Sell0
12-month price target
4,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability
-20,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning OSUR.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to OSUR.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    OraSure Technologies Inc (OSUR.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, focusing on medical devices and related supplies. It is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    OraSure Technologies Inc exhibits a strong liquidity position, with $199.28 million in cash and equivalents and a current ratio of 6.58, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is effectively zero, as it holds only $163,000 in long-term debt against $340.83 million in total equity, suggesting a conservative capital structure. However, the company reported negative operating and free cash flows of -$49.02 million and -$60.32 million, respectively, which may signal operational inefficiencies or high capital expenditures.

    Profitability metrics for OraSure are underperforming relative to industry norms. The company recorded a net loss of $68.73 million and an operating loss of $71.97 million, resulting in a return on equity of -20.17% and a return on assets of -17.05%. These figures are significantly below the industry's median profitability metrics, indicating a need for operational improvements or cost restructuring to align with sector performance.

    OraSure's revenue is concentrated in a single business segment focused on rapid diagnostic tests and related products, with no disclosed geographic diversification in the provided data. This concentration may expose the company to higher risk if demand for its primary product line fluctuates or if regulatory changes impact its operations.

    The company's growth trajectory appears to be under pressure, with a net loss in the most recent reporting period and no clear indication of revenue growth in the outlook. Analysts have assigned a mean price target of $4.00, with a median and high target also at $4.00, and a mean recommendation of 2.00 (indicating a "Hold"). These signals suggest limited upside potential in the near term and a cautious investor sentiment.

    Risk factors for OraSure include its negative operating and free cash flows, which could limit its ability to fund operations or invest in growth without external financing. The company has not disclosed any immediate dilution risks, and its liquidity position remains strong, with no filing-based flags detected. However, the absence of positive cash flow generation may necessitate future capital raises, which could introduce dilution risk if not managed carefully.

    Recent events, as reflected in the financial snapshot, show a continuation of operational losses and negative cash flows. No specific filings or transcripts are cited in the provided data, but the financial results suggest a challenging operating environment for the company.

    Key takeaways
    • OraSure Technologies Inc has a strong liquidity position with $199.28 million in cash and equivalents and a current ratio of 6.58.
    • The company is experiencing significant operational losses, with a net loss of $68.73 million and an operating loss of $71.97 million.
    • OraSure's profitability metrics, including a return on equity of -20.17%, are well below industry medians.
    • The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
    • Analysts have assigned a mean price target of $4.00 and a "Hold" recommendation, indicating limited near-term upside potential.
    • OraSure's negative operating and free cash flows may necessitate future capital raises, which could introduce dilution risk.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $4,25
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $340.8M
    Net cash
    $199.1M
    Current ratio
    6.6
    Debt / equity
    0.0
    ROA
    -17.1%
    ROE
    -20.2%
    Cash conversion
    71.0%
    CapEx / revenue
    -3.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Consumer Health Diagnostics
    low · business_description · 2026-07-03
    In Vitro Diagnostics
    low · business_description · 2026-07-03
    Point-of-Care Diagnostics
    low · business_description · 2026-07-03
    Specimen Management Systems
    low · business_description · 2026-07-03

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setOSUR 0,0% · rank #47 of 84

    Business relationships

    Business relationships7 disclosed relationships · 2 types · extracted from filings & disclosures
    Customers2
    Amazon.Com IncAMZN.OCustomer90%Source ↗
    Walmart IncWMT.OCustomer90%Source ↗
    Subsidiaries5
    EX21:0d0bc9415d3eEX21:0d0bc9415d3eSubsidiarie97%
    EX21:9f475d2cdd7fEX21:9f475d2cdd7fSubsidiarie97%
    EX21:a53a16024731EX21:a53a16024731Subsidiarie97%
    EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%
    EX21:db8e3362e010EX21:db8e3362e010Subsidiarie97%

    Supply chain

    Vendors → OSUR ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSOSUROSUROraSure Technologies Inc7 entitiesAmazon.Com IncDepartment StoresUSWalmart IncFood Retail & DistributiUS
    2 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs OSUR · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    +32,7 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    +29,9 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    +33,7 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    +27,1 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    +23,1 vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    +4,7 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    +51,0 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,85
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-22 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,85
    Revenueno estimateno estimate118,3M USD
    Operating incomeno estimateno estimate-55,6M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy1
    Buy0
    Hold1
    Sell0
    Strong sell0
    12-month price target$4,00 · Median $4,00
    Low $4,00High $4,00
    Operating income · consensus-55,6M USD
    EPS surprise
    −10,6 %
    reported vs consensus · miss
    Revenue surprise
    −2,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$4,00
    Mean$4,00
    Median$4,00
    High$4,00
    Spot$4,25
    −5.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-62,6 %Bottom quartile
    Net Margin-59,8 %Bottom quartile
    ROE-20,2 %Below median
    Capex / Rev-3,6 %Below median
    D/E0,00Above median
    Cash Conv0,71Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • OraSure Technologies Inc Market data — financials · 2026-05-28
    • OraSure Technologies Inc Market data — analyst estimates · 2026-05-28
    • OraSure Technologies Inc Market data — ESG · 2026-05-28

    Ownership & reference

    Top holders

    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$8M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$31M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$3M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$5M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$5M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$10M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Carrie Eglinton MannerPresident, Chief Executive Officer, Director

    Insider activity

    Net buying8 buys · 0 sellsnet $551K9 insiders · last 365d
    • Gagliano Nancy JDirector · Common StockOther 46 106 · 2026-06-03
    • Boyd Steven KyleDirector · Common StockOther 46 106 · 2026-06-03
    • Bertrand John D.Director · Common StockOther 46 106 · 2026-06-03
    • Kenny John P.Director · Common StockOther 46 106 · 2026-06-03
    • Marmora LelioDirector · Common StockOther 46 106 · 2026-06-03
    • McMahon Robert W.Director · Common StockOther 46 106 · 2026-06-03
    • Boyd Steven KyleDirector · Common StockBought 25 000 @ $2,99$75K · 2026-05-14
    • Marmora LelioDirector · Common StockOther 28 406 @ $3,02$86K · 2026-05-13
    • Boyd Steven KyleDirector · Common StockBought 25 000 @ $3,02$76K · 2026-05-13
    • McMahon Robert W.Director · Common StockOther 22 888 @ $3,02$69K · 2026-05-13
    • Gagliano Nancy JDirector · Common StockOther 21 305 @ $3,02$64K · 2026-05-13
    • Bertrand John D.Director · Common StockOther 33 661 · 2026-05-12
    • Boyd Steven KyleDirector · Common StockBought 25 000 @ $2,98$74K · 2026-05-12
    • Boyd Steven KyleDirector · Common StockOther 5 246 @ $3,10$16K · 2026-03-26
    • Boyd Steven KyleDirector · Common StockOther 1 416 @ $3,10$4K · 2026-03-26
    • EGLINTON MANNER CARRIEDirector, President & CEO · Common StockBought 32 300 @ $2,93$95K · 2026-03-20
    • McGrath Kenneth JChief Financial Officer · Common StockBought 32 300 @ $2,93$95K · 2026-03-20
    • EGLINTON MANNER CARRIEDirector, President & CEO · Common StockBought 22 022 @ $3,00$66K · 2026-03-13
    • McGrath Kenneth JChief Financial Officer · Common StockBought 22 021 @ $3,00$66K · 2026-03-13
    • McGrath Kenneth JChief Financial Officer · Common StockOther 88 348 · 2026-03-02
    • Anthony Michele MarieSVP Finance & CAO · Common StockOther 42 982 · 2026-03-02
    • EGLINTON MANNER CARRIEDirector, President & CEO · Common StockOther 355 464 · 2026-03-02
    • EGLINTON MANNER CARRIEDirector, President & CEO · Common StockOther 122 655 @ $3,04$373K · 2026-03-01
    • McGrath Kenneth JChief Financial Officer · Common StockOther 20 745 @ $3,04$63K · 2026-03-01
    • EGLINTON MANNER CARRIEDirector, President & CEO · Common StockOther 129 032 · 2026-03-01

    Short positioning

    3.3Mshares short+9.8% vs prior
    8.97days to cover
    44.9%short of daily vol
    4.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    OSUR.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    OSURAMZN.OWMT.OEX21:0d0EX21:9f4EX21:a53EX21:d30EX21:db8Diversified Me
    This companySectorCustomersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -15.9%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -261.5%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -261.5%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -39.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -252.5%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -279.1%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -154.8%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 63.3%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -38.1%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -16.9%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -10.1%Derived (calculated)
    • Net margin (FY 2025-12-31): -59.8%Derived (calculated)
    • Gross margin (FY 2025-12-31): 41.9%Derived (calculated)
    • Return on equity (FY 2025-12-31): -20.2%Derived (calculated)
    • Return on assets (FY 2025-12-31): -17.0%Derived (calculated)
    • Current ratio (FY 2025-12-31): 6.58xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.18xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 10.5%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -25.6%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -37.2%Derived (calculated)
    • Total assets (annual): USD 403.17MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Operating cash flow (annual): USD -49.02MSEC XBRL filing
    • Cost of revenue (annual): USD 66.82MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-11FILING8-K filing →
    2026-06-03 00:00 UTCINSIDER6 insider transactions — 2026-06
    2026-06-03FILING8-K filing →
    2026-06-03INSIDERGagliano Nancy J transacted 46.1k sh — Director
    2026-06-03INSIDERBoyd Steven Kyle transacted 46.1k sh — Director
    2026-06-03INSIDERBertrand John D. transacted 46.1k sh — Director
    2026-06-03INSIDERKenny John P. transacted 46.1k sh — Director
    2026-06-03INSIDERMarmora Lelio transacted 46.1k sh — Director
    2026-06-03INSIDERMcMahon Robert W. transacted 46.1k sh — Director
    2026-05-14 00:00 UTCINSIDER7 insider transactions — 2026-05 · $444k gross
    2026-05-14INSIDERBoyd Steven Kyle bought 25.0k sh — Director ~$75k
    2026-05-13INSIDERMarmora Lelio transacted 28.4k sh — Director ~$86k
    2026-05-13INSIDERBoyd Steven Kyle bought 25.0k sh — Director ~$76k
    2026-05-13INSIDERMcMahon Robert W. transacted 22.9k sh — Director ~$69k
    2026-05-13INSIDERGagliano Nancy J transacted 21.3k sh — Director ~$64k
    2026-05-12INSIDERBertrand John D. transacted 33.7k sh — Director
    2026-05-12INSIDERBoyd Steven Kyle bought 25.0k sh — Director ~$74k
    2026-05-08FILING10-Q filing →
    2026-05-06FILING8-K filing →
    2026-04-30FILINGDEF 14A filing →
    2026-04-17FILING8-K filing →
    2026-03-30FILING8-K filing →
    2026-03-26 00:00 UTCINSIDER18 insider transactions — 2026-03 · net sell $342k
    2026-03-26INSIDERBoyd Steven Kyle transacted 5.2k sh — Director ~$16k
    2026-03-26INSIDERBoyd Steven Kyle transacted 1.4k sh — Director ~$4k
    2026-03-20INSIDEREGLINTON MANNER CARRIE bought 32.3k sh — Director, President & CEO ~$95k
    2026-03-20INSIDERMcGrath Kenneth J bought 32.3k sh — Chief Financial Officer ~$95k
    2026-03-13INSIDEREGLINTON MANNER CARRIE bought 22.0k sh — Director, President & CEO ~$66k
    2026-03-13INSIDERMcGrath Kenneth J bought 22.0k sh — Chief Financial Officer ~$66k
    2026-03-09FILING10-K filing →
    2026-03-05FILING8-K filing →
    2026-03-02INSIDERMcGrath Kenneth J transacted 88.3k sh — Chief Financial Officer
    2026-03-02INSIDERAnthony Michele Marie transacted 43.0k sh — SVP Finance & CAO
    2026-03-02INSIDEREGLINTON MANNER CARRIE transacted 355.5k sh — Director, President & CEO
    2026-03-01INSIDEREGLINTON MANNER CARRIE transacted 122.7k sh — Director, President & CEO ~$373k
    Showing the 40 most recent of 49 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage